BNTC Stock Price, Benitec Biopharma Ltd Quote, Chart

Market Summary

USD9.32-0.15

Delayed

-1.58%

BNTC Stock Price

View Fullscreen

BNTC RSI Chart

BNTC Valuation

Market Cap

87.3M

Price/Earnings (Trailing)

-4.02

Price/Sales (Trailing)

1.0K

Price/Free Cashflow

-3.87

BNTC Price/Sales (Trailing)

BNTC Profitability

Return on Equity

-188.63%

Return on Assets

-144.62%

Free Cashflow Yield

-25.85%

BNTC Fundamentals

BNTC Revenue

Revenue (TTM)

75.0K

BNTC Earnings

Earnings (TTM)

-21.7M

Earnings Growth (Yr)

2.68%

Earnings Growth (Qtr)

37.06%

Breaking Down BNTC Revenue

Last 7 days

0.8%

Last 30 days

94.2%

Last 90 days

212.8%

Trailing 12 Months

178.2%

How does BNTC drawdown profile look like?

BNTC Financial Health

Current Ratio

4.18

BNTC Investor Care

Shares Dilution (1Y)

469.12%

Diluted EPS (TTM)

-8.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	116.0K	75.0K	0	0
2022	82.0K	74.0K	0	87.0K
2021	1.8M	123.0K	0	102.5K
2020	8.7M	7.0M	5.3M	3.6M
2019	0	12.2M	10.5M	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Benitec Biopharma Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 11, 2023	buchi j kevin	bought	-	-	51,813	-
Aug 11, 2023	boston megan	bought	-	-	25,907	executive director
Dec 09, 2021	oliveira steven michael	bought	32,126	3.0443	10,553	-
Nov 29, 2021	oliveira steven michael	bought	120,687	3.1804	37,947	-
May 03, 2021	oliveira steven michael	bought	172,275	4.2537	40,500	-
Apr 30, 2021	oliveira steven michael	bought	501,888	4.1824	120,000	-
Apr 29, 2021	oliveira steven michael	bought	125,618	5.491	22,877	-
Apr 28, 2021	oliveira steven michael	bought	544,860	5.4486	100,000	-

Which funds bought or sold BNTC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	added	131	45,477	61,950	-%
May 15, 2024	SUVRETTA CAPITAL MANAGEMENT, LLC	unchanged	-	412,524	1,072,160	0.04%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-30.06	1,102	9,161	-%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	unchanged	-	382,160	993,237	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	35.53	677,460	1,266,460	-%
May 13, 2024	FRANKLIN RESOURCES INC	added	0.01	1,106,260	3,012,150	-%
May 13, 2024	UBS Group AG	reduced	-17.68	681	2,689	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	18,845	51,322	-%
May 10, 2024	GROUP ONE TRADING, L.P.	unchanged	-	168	456	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	34.00	89.00	-%

Are Funds Buying or Selling BNTC?

Are funds buying BNTC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BNTC

No. of Funds

Unveiling Benitec Biopharma Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 29, 2024	suvretta capital management, llc	17.4%	1,478,490	SC 13D
Apr 29, 2024	oliveira steven michael	8.39%	746,324	SC 13G
Apr 29, 2024	hbm healthcare investments (cayman) ltd.	9.99%	849,893	SC 13G
Apr 11, 2024	adage capital partners gp, l.l.c.	9.99%	264,510	SC 13G/A
Feb 14, 2024	citadel advisors llc	3.4%	6	SC 13G/A
Feb 13, 2024	janus henderson group plc	7.0%	180,399	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	9.9%	262,843	SC 13G/A
Dec 11, 2023	franklin resources inc	22.9%	588,237	SC 13G/A
Sep 11, 2023	franklin resources inc	28.5%	588,235	SC 13G/A
Aug 25, 2023	adage capital partners gp, l.l.c.	7.50%	189,188	SC 13G

Recent SEC filings of Benitec Biopharma Ltd

View All Filings

Date Filed	Form Type	Document
May 16, 2024	S-1	Initial Public Offering
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 02, 2024	3	Insider Trading
Apr 29, 2024	SC 13D	13D - Major Acquisition
Apr 29, 2024	SC 13G	Major Ownership Report
Apr 29, 2024	SC 13G	Major Ownership Report
Apr 25, 2024	D	D
Apr 19, 2024	8-K	Current Report
Apr 18, 2024	8-K	Current Report

Peers (Alternatives to Benitec Biopharma Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Benitec Biopharma Ltd News

Latest updates

Benitec Biopharma Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q2	2023Q1	2022Q4	2022Q2	2022Q1	2021Q4	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q3	2019Q2
Revenue	-100.0%	-	7.00	54.00	14.00	-	48.00	25.00	1.00	8.00	71.00	134	81.00	28.00	-	-
Operating Expenses	-9.1%	4,141	4,557	4,395	5,624	4,738	3,508	4,860	3,857	3,794	3,260	2,745	2,855	2,139	1,199	-
S&GA Expenses	-100.0%	-	1,371	1,228	1,863	1,553	1,337	1,714	1,536	1,029	2,111	1,837	1,767	1,287	750	-
R&D Expenses	-19.5%	2,566	3,186	3,167	3,761	3,176	2,171	3,146	2,320	2,758	1,168	774	1,040	805	423	-
Net Income	8.2%	-4,279	-4,661	-4,397	-5,411	-5,067	-3,275	-4,821	-4,003	-3,909	-3,252	-2,718	-2,935	-2,102	-1,147	-
Net Income Margin	-10.9%	-289.23*	-260.83*	-172.14*	-216.62*	-246.05*	-209.07*	-173.44*	-112.86*	-	-	-	-	-	-	-
Free Cashflow	-52.1%	-6,211	-4,084	-4,030	-5,868	-4,868	-3,444	-3,322	-5,016	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q2
Assets	-29.8%	15.00	21.00	27.00	4.00	8.00	12.00	18.00	6.00	10.00	14.00	18.00	21.00	13.00	16.00	9.00	12.00	19.00
Current Assets	-30.9%	14.00	21.00	26.00	4.00	7.00	11.00	17.00	5.00	9.00	13.00	16.00	21.00	12.00	14.00	8.00	11.00	19.00
Cash Equivalents	-30.5%	14.00	20.00	26.00	2.00	7.00	11.00	17.00	4.00	9.00	12.00	16.00	20.00	12.00	14.00	7.00	10.00	16.00
Net PPE	300.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00
Liabilities	-40.5%	3.00	6.00	5.00	4.00	4.00	3.00	4.00	3.00	3.00	3.00	2.00	1.00	2.00	1.00	1.00	1.00	3.00
Current Liabilities	-40.2%	3.00	6.00	5.00	4.00	3.00	2.00	3.00	3.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00	3.00
Shareholder's Equity	-25.7%	12.00	15.00	22.00	0.00	5.00	9.00	15.00	3.00	8.00	11.00	15.00	20.00	11.00	15.00	8.00	10.00	17.00
Retained Earnings	-2.4%	-184	-180	-173	-167	-163	-158	-153	-148	-143	-139	-135	-130	-126	-122	-119	-116	-108
Additional Paid-In Capital	0.1%	197	197	197	169	169	169	169	152	152	152	152	152	139	138	129	129	127
Shares Outstanding	5.1%	3.00	3.00	3.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-
Float	-	-	-	-	-	-	5.00	-	-	-	21.00	-	-	-	14.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-17.2%	-6,210	-5,300	-4,600	-4,083	-4,017	-5,855	-4,045	-4,855	-3,444	-3,322	-4,278	-5,157	-1,975	-3,340	-2,360	-3,145	-769	-3,076	-545	-
Share Based Compensation	106.5%	192	93.00	91.00	127	71.00	-48.00	302	168	192	239	271	279	235	82.00	38.00	57.00	88.00	37.00	55.00	-
Cashflow From Investing	-Infinity%	-179	-	-	-	-	-	-	-13.00	-	-	-	141	-15.00	-174	-173	-13.00	-	-82.00	1.00	-
Cashflow From Financing	-100.0%	-	39.00	27,919	-	-	-	16,015	-	-	-	-	12,668	3.00	-	-	-	-	-	1,770	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BNTC Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Licensing revenues from customers	$ 0	$ 54	$ 0	$ 68
Total revenues	0	54	0	68
Operating expenses:
Royalties and license fees	(3)	0	(108)	0
Research and development	2,566	3,167	12,097	9,588
General and administrative	1,578	1,228	4,953	5,011
Total operating expenses	4,141	4,395	16,942	14,599
Loss from operations	(4,141)	(4,341)	(16,942)	(14,531)
Other income (loss):
Foreign currency transaction loss	(118)	(45)	(22)	(391)
Interest expense, net	(4)	(7)	(16)	(25)
Other income (expense), net	(16)	0	(50)	50
Unrealized loss on investment	0	(4)	(1)	(4)
Total other income (loss), net	(138)	(56)	(89)	(370)
Net loss	(4,279)	(4,397)	(17,031)	(14,901)
Other comprehensive income (loss):
Unrealized foreign currency translation gain (loss)	117	45	(5)	392
Total other comprehensive income (loss)	117	45	(5)	392
Total comprehensive loss	$ (4,162)	$ (4,352)	$ (17,036)	$ (14,509)
Net loss per share: basic	$ (1.64)	$ (2.67)	$ (6.95)	$ (11.47)
Net loss per share: diluted	$ (1.64)	$ (2.67)	$ (6.95)	$ (11.47)
Weighted average number of shares outstanding: basic	2,616,288	1,645,951	2,449,295	1,299,423
Weighted average number of shares outstanding: diluted	2,616,288	1,645,951	2,449,295	1,299,423

BNTC Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Current assets:
Cash at bank	$ 14,143	$ 2,477
Restricted cash	13	13
Trade and other receivables	53	55
Prepaid and other assets	157	1,184
Total current assets	14,366	3,729
Property and equipment, net	204	87
Deposits	25	25
Prepaid and other assets	69	97
Right-of-use assets	335	526
Total assets	14,999	4,464
Current liabilities:
Trade and other payables	2,628	3,231
Accrued employee benefits	517	472
Lease liabilities, current portion	292	275
Total current liabilities	3,437	3,978
Lease liabilities, less current portion	62	284
Total liabilities	3,499	4,262
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock, $0.0001 par value—160,000,000 shares authorized; 2,724,794 shares and 1,671,485 shares issued and outstanding at March 31, 2024 and June 30, 2023, respectively	0	0
Additional paid-in capital	197,255	168,921
Accumulated deficit	(184,920)	(167,889)
Accumulated other comprehensive loss	(835)	(830)
Total stockholders' equity	11,500	202
Total liabilities and stockholders' equity	$ 14,999	$ 4,464

About Benitec Biopharma Ltd

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

CEO	Dr. Jerel A. Banks M.D., Ph.D.
WEBSITE	https://benitec.com
INDUSTRY	Biotechnology
EMPLOYEES	18

Benitec Biopharma Ltd Frequently Asked Questions

What is the ticker symbol for Benitec Biopharma Ltd? What does BNTC stand for in stocks?

BNTC is the stock ticker symbol of Benitec Biopharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Benitec Biopharma Ltd (BNTC)?

As of Fri May 17 2024, market cap of Benitec Biopharma Ltd is 87.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BNTC stock?

You can check BNTC's fair value in chart for subscribers.

What is the fair value of BNTC stock?

You can check BNTC's fair value in chart for subscribers. The fair value of Benitec Biopharma Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Benitec Biopharma Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BNTC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Benitec Biopharma Ltd a good stock to buy?

The fair value guage provides a quick view whether BNTC is over valued or under valued. Whether Benitec Biopharma Ltd is cheap or expensive depends on the assumptions which impact Benitec Biopharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BNTC.

What is Benitec Biopharma Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BNTC's PE ratio (Price to Earnings) is -4.02 and Price to Sales (PS) ratio is 1.04 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BNTC PE ratio will change depending on the future growth rate expectations of investors.